<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616499</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582623</org_study_id>
    <secondary_id>YONSEI-4-2006-0136</secondary_id>
    <secondary_id>ZENECA-YONSEI-4-2006-0136</secondary_id>
    <nct_id>NCT00616499</nct_id>
  </id_info>
  <brief_title>Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving Gefitinib before surgery may make the tumor smaller and reduce&#xD;
      the amount of normal tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with&#xD;
      stage IIIA non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the response rate to gefitinib treatment as preoperative induction therapy in&#xD;
           patients with biopsy-proven stage IIIA (pN2) non-squamous non-small cell lung cancer&#xD;
           accompanied by epidermal growth factor receptor (EGFR) mutations.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the complete resection rate in patients treated with this drug.&#xD;
&#xD;
        -  To determine the overall survival rate in patients treated with this drug.&#xD;
&#xD;
        -  To determine the disease-free survival rate in patients treated with this drug.&#xD;
&#xD;
        -  To determine the pathologic complete response rate in patients treated with this drug.&#xD;
&#xD;
        -  To determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral gefitinib once a day on days 1-28. Treatment repeats every 28 days for&#xD;
      up to 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients with resectable disease may undergo surgery.&#xD;
      Patients with unresectable disease may undergo surgery, chemotherapy, and/or radiotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete resection rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete pathological response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy-proven stage IIIA nonsquamous non-small cell lung cancer&#xD;
&#xD;
               -  pN2 disease proven by mediastinoscopy&#xD;
&#xD;
          -  Meets any of the following criteria:&#xD;
&#xD;
               -  Never smoked&#xD;
&#xD;
               -  EGFR mutations (in exon 18, 19, or 21)*&#xD;
&#xD;
               -  FISH positive for EGFR* NOTE: *Irrespective of smoking history&#xD;
&#xD;
          -  Presence of at least 1 unidimensionally measurable lesion on thoracic CT scan,&#xD;
             according to RECIST&#xD;
&#xD;
          -  Feasible to undergo pneumonectomy or lobectomy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  FEV_1 ≥ 2.0 L in preoperative pulmonary function test&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  WBC 4,000-12,000/μL&#xD;
&#xD;
          -  ANC ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3.0 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 3.0 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Severe complications or infections&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Clinically significant heart disease&#xD;
&#xD;
          -  Uncontrolled hepatitis, chronic liver disease, or diabetes mellitus&#xD;
&#xD;
          -  Another active cancer except properly treated carcinoma in situ of the cervix or&#xD;
             basal/squamous cell skin carcinoma&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy, chemotherapy, hormone therapy, or target therapy&#xD;
&#xD;
          -  No other concurrent systemic anticancer therapies, including experimental drugs,&#xD;
             chemotherapy, immunotherapy, or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Hang Kim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>82-2-2072-1742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hang Kim, MD</last_name>
      <phone>82-2-2228-8131</phone>
      <email>kjhang@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>82-2-3410-1247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center - University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>82-2-3010-7282</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

